Drug Trial Radar · NCT06527404
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
469
Actual
Start
Jul 18, 2024
Primary completion
Apr 17, 2026
Study completion Jun 25, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
Conditions
- Prurigo Nodularis
Interventions
RocatinlimabDrug
SC Injection
PlaceboDrug
SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Week 24Time frame: Up to 24 weeks
- US Only: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score and Prurigo Nodularis Stage Assessment at Week 24Time frame: Up to 24 weeks
Locations
192 sites in 30 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
First OC Dermatology
Fountain Valley, California
Los Angeles Universal Research Center
Los Angeles, California
Paradigm Clinical Research Center Inc
San Diego, California
Wolverine Clinical Trials
Santa Ana, California
Direct Helpers Research Center
Hialeah, Florida
Southern Clinical Research
Miami, Florida
University of Miami Hospital
Miami, Florida
Miami Dermatology and Laser Institute
Miami, Florida
Wellness Clinical Research
Miami Lakes, Florida
Clinical Research Trials of Florida Inc
Tampa, Florida
Olympian Clinical Research - Tampa
Tampa, Florida
Emory University
Atlanta, Georgia
Endeavor Health Clinical Trials Center
Skokie, Illinois
The Indiana Clinical Trials Center PC
Plainfield, Indiana
Revival Research Institute, LLC
Troy, Michigan
Icahn School of Medicine at Mount Sinai
New York, New York
Optima Research
Boardman, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Wright State Physicians
Fairborn, Ohio
Hightower Clinical
Oklahoma City, Oklahoma
Center For Clinical Studies PLLC
Houston, Texas
Clarity Dermatology
Lancaster, Texas
Springville Dermatology
Springville, Utah
Parra Dermatologia
Mendoza, Argentina
Hospital Universitario Austral
Derqui, Pilar, Buenos Aires, Argentina
Instituto de Investigaciones Clinicas de Cordoba
Córdoba, Córdoba Province, Argentina
Instituto de Neumonologia y Dermatologia
Buenos Aires, Distrito Federal, Argentina
Derma Internacional
Buenos Aires, Distrito Federal, Argentina
Centro de investigacion clinica y epidemiologica
San Miguel D Tucuman, Tucumán Province, Argentina
St George Dermatology and Skin Cancer Centre
Kogarah, New South Wales, Australia
Veracity Clinical Research
Woolloongabba, Queensland, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
Medizinische Universitaet Graz
Graz, Austria
Ordensklinikum Linz Elisabethinen
Linz, Austria
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
Brussels, Belgium
Universitaire Ziekenhuizen Leuven Gasthuisberg
Leuven, Belgium
Centre Hospitalier Universitaire de Liege - Sart Tilman
Liège, Belgium
Showing 40 of 192 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.